You are here:
Direct Healthcare Professional Communication (DHPC) on systemic and inhaled fluoroquinolones: risk of heart valve regurgitation/incompetence
2020.10.29
Active substance: fluoroquinolones
The marketing authorisation holders of fluoroquinolone antibiotics products in agreement with the European Medicines Agency and the Federal Institute for Drugs and Medical Devices would like to inform you about the risk of heart valve regurgitation/incompetence associated with fluoroquinolones for systemic and inhalation use. In patients at risk for heart valve regurgitation/incompetence, systemic and inhaled fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN